doxorubicin
Cold Chain RequiredFDA Approved, EMA Approved
Description
Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death. It is widely used in the treatment of various sarcomas including extraskeletal myxoid chondrosarcoma as part of combination chemotherapy regimens. It has broad activity against multiple malignancies.
Indications & Therapeutic Use
soft tissue sarcoma, extraskeletal myxoid chondrosarcoma, breast cancer, lymphoma, acute leukemia
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
doxorubicin
| Generic Name | doxorubicin |
| Brands | 1 brand available |
| Active Ingredient | doxorubicin hydrochloride |
| Drug Class | soft tissue sarcoma |
| Manufacturer | Multiple manufacturers |
| Dosage Forms | IV injection, 2 mg/mL solution |
| Medical Code | L01DB01 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00003052 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes